MP Journal of Medical Research
Presented at Journée scientifique de l'APIRR, Rabat, 2–4 September 2026 · All posters from this congress
OncologyOpen accessPoster communication · 2026-0004

Targeted therapy in Oncology: breast cancer

English version of a poster presented in French.

Meryem Chennaq1,2,3✉, Ismail Naffi1,2, Safaa El Medkouri1,2,3, Yahia Cherrah1

  1. 1 Faculty of Medicine and Pharmacy, Mohammed V University in Rabat
  2. 2 Ibn Sina University Hospital Center
  3. 3 National Institute of Oncology, Ibn Sina University Hospital

Received 30 September 2026 · Accepted 30 September 2026 · Published 30 September 2026 · Corrected 9 November 2026

DOI: https://doi.org/10.5281/zenodo.23067714

Article PDF · Original poster (PDF)

views
37
downloads
18
countries
14

Since publication · journal site and Zenodo archive · robots excluded

Schéma illustrant les mécanismes d'action des thérapies ciblées sur les cellules cancéreuses du sein.
Schéma illustrant les mécanismes d'action des thérapies ciblées sur les cellules cancéreuses du sein.Click or press Esc to close

Key messages

  1. Les anticorps monoclonaux ciblant HER2 et VEGF sont essentiels dans le traitement du cancer du sein métastatique.
  2. Les petites molécules ciblent des voies spécifiques comme CDK 4/6, PARP et PI3K/AKT/mTOR pour inhiber la progression tumorale.
  3. Les thérapies conjuguées (ADC) permettent de délivrer des agents cytotoxiques directement à l'intérieur des cellules cancéreuses.

Abstract

Introduction

Breast cancer is the most common cancer worldwide, affecting more than 2.3 million women globally.

Materials and methods

This poster presents a literature review on the different pharmacological mechanisms of targeted therapies used in breast cancer.

Results

Targeted therapies are classified into several categories: monoclonal antibodies (targeting HER2, VEGF), small molecules (targeting CDK 4/6, PARP, PI3K/AKT/mTOR pathway), and conjugated therapies (ADC: Antibody-drug Conjugates). Each category includes examples of drugs and their specific modes of action.

Conclusion

Targeted therapies represent a major advancement in the treatment of breast cancer, especially for patients with aggressive forms such as HER2-positive cancer.

Original poster

Keywords
breast cancer · targeted therapy · monoclonal antibodies · small molecules · HER2 · VEGF · CDK 4/6 · PARP · PI3K/AKT/mTOR · ADC
Received
30 September 2026
Accepted
30 September 2026
Published
30 September 2026
Peer review
Single-anonymized review by the Editorial Board · How we review
Version history
  • 30 September 2026 — first published
  • 5 October 2026 — corrected: English version, abstract, article type, authors, award, congress details, figure caption, key messages, keywords, language, license, record, references, related publication, specialty, title, video
  • 9 November 2026 — corrected: English version, abstract, article type, authors, award, congress details, figure caption, key messages, keywords, language, license, record, references, related publication, specialty, title, video
DOI
https://doi.org/10.5281/zenodo.23067714
License
© The Authors 2026. Distributed under CC BY 4.0
Journal
MP Journal of Medical Research · ISSN 3144-8402

Related posters

OncologyRisk of Chondrosarcoma Transformation from Multiple Hereditary Exostosis Under the Age of 18, and Suggestion for Screening Protocol. Literature Review.H. Al Saidi, A. Al Sariri, A. Al Omairi and 3 othersOncologyMeasles in Pediatric OncologyF. Kouzi, K. Elmkaddem, S. Bouramdane and 1 otherOncologyUnusual EMA and pan-keratin negative epithelioid sarcomaA. Alpeza, K. Gregorović, D. Alpeza and 4 othersOncologyIn Silico Discovery and Bioactivity of Beta-Carboline Derivatives as Potential Payloads for Chitosan-Based Breast Cancer Delivery SystemsM. Izzuddin, N. Pungot, M. Jamil and 4 others
Poster (PDF)Cite